HOME > Articles >

Korean J Gastroenterol  <  Volume 74(6); 2019 <  Articles

Korean J Gastroenterol 2019; 74(6): 333-340  https://doi.org/10.4166/kjg.2019.74.6.333
Knowledge and Viewpoints on Biosimilar Monoclonal Antibodies among Asian Physicians: Comparison with European Physicians
Soo-Kyung Park, Won Moon1, Eun Soo Kim2, Sang Hyun Park and Dong Il Park
Division of Gastroenterology, Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul; Department of Internal Medicine, Kosin University College of Medicine1, Busan; Division of Gastroenterology and Hepatology, Department of Internal Medicine, Kyungpook National University School of Medicine2, Daegu, Korea
Correspondence to: Dong Il Park, Division of Gastroenterology, Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, 29 Saemunan-ro, Jongno-gu, Seoul 03181, Korea. Tel: +82-2-2001-2059, Fax: +82-2-2001-2049, E-mail: diksmc.park@samsung.com, ORCID: https://orcid.org/0000-0003-2307-8575
Received: June 10, 2019; Revised: August 9, 2019; Accepted: September 6, 2019; Published online: December 25, 2019.
© The Korean Journal of Gastroenterology. All rights reserved.

This is an open access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Background/Aims: Current knowledge and viewpoints regarding biosimilars among physicians in Asia are unknown, even though these were investigated by European Crohn’s and Colitis Organization (ECCO) members in 2013 and 2015. Thus, this study conducted a multinational survey to assess the awareness of biosimilar monoclonal antibodies among Asian physicians.
Methods: A 17-question multiple-choice anonymous web survey was conducted with the logistic support of the Asian Organization of Crohn’s and Colitis (AOCC). Randomly selected AOCC members were invited by e-mail to participate between February 24, 2017 and March 26, 2017.
Results: In total, 151 physicians from eight Asian countries responded to the survey. Most of the participants were gastroenterologists (96.6%), and 77.5% had cared for inflammatory bowel diseases (IBD) patients for more than 5 years. The majority of the respondents (66.2%) were aware that a biosimilar is similar but not equivalent to the originator. The majority of respondents (77.5%) considered cost saving to be the main advantage of biosimilars, but a high percentage of respondents (38.4%) were concerned about a different immunogenicity from that of the originator (92.4% and 27.1% respectively in ECCO 2015). Only 19.2% considered that the originator and biosimilars were interchangeable, and only 6.0% felt very confident in the use of biosimilars (44.4% and 28.8% respectively in ECCO 2015).
Conclusions: Asian gastroenterologists in 2017 are generally well informed about biosimilars. On the other hand, compared to the ECCO members surveyed in 2015, Asian gastroenterologists had more concerns and less confidence about the use of biosimilars in clinical practice. Thus, IBD-specific data on the comparison of the efficacy, safety, and immunogenicity in Asian patients are needed.
Keywords: Biosimilar pharmaceuticals; Infliximab; Asia

This Article

Author ORCID Information

Stats or Metrics
  • View: 79
  • Download: 81

Social Network Service



Official Journal of

Indexed/Covered by

  • thomson reuters
  • pubmedcentral
  • koreamed
  • crossref
  • crossref
  • synepse
  • kofst
  • DOAJ